MFN Drug Pricing Divides Trump White House and Congress

By FieldPulse Staff · March 17, 2026

Tags: strategy, leadership

Conservative groups call MFN drug pricing 'imported socialist price controls,' fracturing Republican support. Novo, J&J, and Pfizer all cite MFN exposure in guidance.

Despite the Trump administration's push to codify most-favored-nation (MFN) drug pricing into law, a coalition of more than 50 conservative and free-market organizations sent a letter to congressional leaders on March 17, 2026 opposing the measure — calling it "imported socialist price controls" that would harm U.S.

pharmaceutical innovation.

The divide exposes a fault line within the Republican coalition: the White House wants mandatory MFN pricing anchored to reference prices in peer countries like the UK and Germany, while the traditional free-market wing of the party argues the policy would undermine the investment incentives that produced the COVID vaccines and GLP-1 breakthroughs.

For pharma companies, the uncertainty is a significant overhang.

Novo Nordisk, J&J, and Pfizer have all cited MFN exposure in 2026 earnings guidance.

Meanwhile, congressional Democrats are largely supportive of the pricing mechanism but object to other elements of the budget reconciliation bill, complicating any path to legislation.

The MFN deals currently on TrumpRx.gov remain voluntary and unenforceable.

Source: https://www.statnews.com/2026/03/17/mfn-drug-pricing-divide-trump-congress-talks/